title: Analysis of a homologous series of perfluorocarboxylates from American Red Cross adult blood donors, 2000-2001 and 2006.
abstract: The purpose of this study was to determine the concentration trends of a nine-target-analyte homologous series of perfluorocarboxylates from six American Red Cross adult blood donor centers. A total of 645 serum and 600 plasma samples were obtained in 2000-2001 and 2006, respectively, with samples stratified for each 10-year (20-69) age- and sex-group per each location. Samples were extracted by protein precipitation and quantified by using tandem mass spectrometry. The nine perfluorocarboxylates were perfluorobutanoate (PFBA, C(3)F(7)CO(2)(-)), perfluoropentanoate (PFPeA, C(4)F(9)CO(2)(-)), perfluorohexanoate (PFHxA, C(5)F(11)CO(2)(-)), perfluoroheptanoate (PFHpA, C(6)F(13)CO(2)(-)), perfluorooctanoate (PFOA, C(7)F(15)CO(2)(-)), perfluorononanoate (PFNA, C(8)F(17)CO(2)(-)), perfluorodecanoate (PFDA, C(9)F(19)CO(2)(-)), perfluoroundecanoate (PFUnA,C(10)F(21)CO(2)(-)), and perfluorododecanoate (PFDoA, C(11)F(23)CO(2)(-)). The majority of measurements were less than the lower limit of quantitation for PFPeA, PFHxA, and PFDoA. For the remaining targeted analytes, the geometric mean serum and plasma concentrations (ng/mL) for 2000-2001 and 2006 were, respectively, as follows: PFBA 2.61 vs 0.33, PFHpA 0.13 vs 0.09, PFOA 4.70 vs 3.44, PFNA 0.57 vs 0.97, PFDA 0.16 vs 0.34, and PFUnA 0.10 vs 0.18. Estimates of the 95th percent tolerance limits (ng/mL) were as follows: PFBA 5.3 vs 1.4, PFHpA 0.4 vs 0.4, PFOA 12.3 vs 7.7, PFNA 1.4 vs 2.2, PFDA 0.4 vs 0.8, and PFUnA 0.3 vs 0.5. Important observations were the decline in PFBA and increase in PFNA, PFDA, and PFUnA concentrations between 2000-2001 and 2006. The longer chain length perfluorocarboxylates were also highly correlated with each other.
authors.affiliation: Medical Department, 3M Company , St. Paul, Minnesota, United States. gwolsen@mmm.com
authors.forename: Geary W
authors.initials: GW
authors.lastname: Olsen
authors.forename: Mark E
authors.initials: ME
authors.lastname: Ellefson
authors.forename: David C
authors.initials: DC
authors.lastname: Mair
authors.forename: Timothy R
authors.initials: TR
authors.lastname: Church
authors.forename: Corinne L
authors.initials: CL
authors.lastname: Goldberg
authors.forename: Ross M
authors.initials: RM
authors.lastname: Herron
authors.forename: Zahra
authors.initials: Z
authors.lastname: Medhdizadehkashi
authors.forename: John B
authors.initials: JB
authors.lastname: Nobiletti
authors.forename: Jorge A
authors.initials: JA
authors.lastname: Rios
authors.forename: William K
authors.initials: WK
authors.lastname: Reagen
authors.forename: Larry R
authors.initials: LR
authors.lastname: Zobel
mesh_terms: D000328:Adult; D017677:Age Distribution; D000368:Aged; D001782:Blood Donors; D016001:Confidence Intervals; D005260:Female; D005466:Fluorocarbons / Q000097:blood*; D006801:Humans; D057230:Limit of Detection; D008297:Male; D008875:Middle Aged; D011785:Quality Assurance, Health Care; D012011:Red Cross; D055815:Young Adult
chemical_list: D005466:Fluorocarbons